Maze Therapeutics Inc (MAZE)

01:17 AM

Q2 Earnings Estimate for MAZE Issued By HC Wainwright - Defense World

01:17 AM

Jul 25, 2025

What analysts say about Maze Therapeutics Inc. stockExceptional profit potential - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Why Maze Therapeutics Inc. stock attracts strong analyst attentionPredictable High Return Trades - Newser

Jul 25, 2025

Jul 24, 2025

What makes Maze Therapeutics Inc. stock price move sharplyFree Stock Market Entry & Exit Signals - Newser

Jul 24, 2025

Jul 24, 2025

What institutions are buying Maze Therapeutics Inc. stock nowFree Trading Strategy Suggestions - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

What drives Maze Therapeutics Inc. stock priceExtraordinary performance - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional

Jul 23, 2025

Jul 23, 2025

This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jul 23, 2025

Jul 23, 2025

H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK

Jul 23, 2025

Jul 23, 2025

Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks

Jul 23, 2025

Jul 23, 2025

Is Maze Therapeutics Inc. a good long term investmentHigh-velocity gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World

Jul 23, 2025

Jul 19, 2025

how maze therapeutics inc. stock performs during market volatilityDaily Trade Opportunity - Newser

Jul 19, 2025

Jul 15, 2025

How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser

Jul 15, 2025

Jul 11, 2025

Maze Therapeutics (NASDAQ:MAZE) Research Coverage Started at Wedbush - Defense World

Jul 11, 2025

Jul 11, 2025

Q2 Earnings Estimate for Maze Therapeutics Issued By Wedbush - Defense World

Jul 11, 2025

Jul 11, 2025

Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $23.50 - Defense World

Jul 11, 2025

Jul 10, 2025

Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire

Jul 10, 2025

Jul 10, 2025

Maze Therapeutics Showcases Precision Medicine Pipeline at Major Kidney and Biotech Investor Conferences - Stock Titan

Jul 10, 2025

Jul 10, 2025

Maze Therapeutics Soars 11.68% on Wedbush's Outperform Rating - AInvest

Jul 10, 2025

Jul 08, 2025

Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says - MarketScreener

Jul 08, 2025

May 29, 2025

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference - GlobeNewswire

May 29, 2025

May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025

May 21, 2025

Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (SSKN), Ionis Pharmaceuticals (IONS) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

May 21, 2025